Key facts
- Notable investors include Wenming Investment.
- Status: Privately Held (backing).
Investors
1- ·The complete investor list — 1 names
- ·Watchlist + deal alerts for Nuclide Tongchuang
- ·The full record, as it builds
Funding rounds
No funding rounds for Nuclide Tongchuang are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About Nuclide Tongchuang
Manufacturer of advanced isotopic materials intended for medical diagnostic and therapeutic applications. The company offers high-energy accelerator systems, multi-isotope production capabilities, and radiopharmaceutical development processes, enabling the healthcare sector to access domestically sourced isotopes for improved clinical availability, reduced import dependency, and enhanced precision in nuclear medicine treatments.
- Sector
- Healthcare
- HQ
- Chongqing, China
- Founded
- 2022
- Ownership
- Privately Held (backing)
Nuclide Tongchuang doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in Nuclide Tongchuang shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on Nuclide Tongchuang in its N-PORT filings yet. We sweep new filings monthly.